1. Generics Bulletin
  2. >>Policy & Regulation

European Parliament Urges Increased Role For Generics And Biosimilars

Industry Welcomes Call For A ‘Greater Market Presence’ For Off-Patent Drugs

 
• By Dave Wallace

A report adopted by the European Parliament calling for measures to support a “greater market presence for generic and biosimilar medicines” has been welcomed by Medicines for Europe.

European parliament chamber
The European Parliament has adopted a report urging a greater presence for generics and biosimilars • Source: Alamy

A report calling for “measures to support a greater market presence for generic and biosimilar medicines” that has been adopted by an overwhelming majority in the European Parliament has been welcomed by industry association Medicines for Europe as a “highly encouraging” step towards increasing access to off-patent medicines.

The report, which represents the European Parliament’s contribution to the European Commission’s plan to update EU pharmaceutical legislation in 2022 – as part of a pharmaceutical strategy unveiled in late 2020 (Also see "EU Pharma Strategy Will Remove Barriers And Bolster

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Generics Bulletin

Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab Competition

 
• By Dean Rudge

Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By Dave Wallace

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.

Medicines UK Welcomes NHS England’s Best-Value Biologics Biosimilar Adoption Framework

 
• By Adam Zamecnik

Reflecting on recent initiatives by NHS England and the MHRA, the newly renamed trade body Medicines UK has welcomed efforts in promoting the use of biosimilars in Britain.